JP2017105819A5 - - Google Patents

Download PDF

Info

Publication number
JP2017105819A5
JP2017105819A5 JP2017022249A JP2017022249A JP2017105819A5 JP 2017105819 A5 JP2017105819 A5 JP 2017105819A5 JP 2017022249 A JP2017022249 A JP 2017022249A JP 2017022249 A JP2017022249 A JP 2017022249A JP 2017105819 A5 JP2017105819 A5 JP 2017105819A5
Authority
JP
Japan
Prior art keywords
xaa
lys
gly
glu
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017022249A
Other languages
English (en)
Japanese (ja)
Other versions
JP6687557B2 (ja
JP2017105819A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017105819A publication Critical patent/JP2017105819A/ja
Publication of JP2017105819A5 publication Critical patent/JP2017105819A5/ja
Application granted granted Critical
Publication of JP6687557B2 publication Critical patent/JP6687557B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017022249A 2013-07-04 2017-02-09 Glp−1様ペプチドの誘導体及びその使用 Active JP6687557B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP13175094 2013-07-04
EP13175094.5 2013-07-04
US201361845646P 2013-07-12 2013-07-12
US61/845,646 2013-07-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015563070A Division JP6139712B2 (ja) 2013-07-04 2014-07-02 Glp−1様ペプチドの誘導体及びその使用

Publications (3)

Publication Number Publication Date
JP2017105819A JP2017105819A (ja) 2017-06-15
JP2017105819A5 true JP2017105819A5 (enExample) 2017-08-24
JP6687557B2 JP6687557B2 (ja) 2020-04-22

Family

ID=48703344

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015563070A Active JP6139712B2 (ja) 2013-07-04 2014-07-02 Glp−1様ペプチドの誘導体及びその使用
JP2017022249A Active JP6687557B2 (ja) 2013-07-04 2017-02-09 Glp−1様ペプチドの誘導体及びその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2015563070A Active JP6139712B2 (ja) 2013-07-04 2014-07-02 Glp−1様ペプチドの誘導体及びその使用

Country Status (11)

Country Link
US (2) US9498534B2 (enExample)
EP (1) EP3016975B1 (enExample)
JP (2) JP6139712B2 (enExample)
KR (1) KR20160029079A (enExample)
CN (1) CN105377884B (enExample)
AR (1) AR096789A1 (enExample)
AU (1) AU2014286234A1 (enExample)
BR (1) BR112015032875A2 (enExample)
CA (1) CA2916311A1 (enExample)
MX (1) MX2015016875A (enExample)
WO (1) WO2015000942A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014283221A1 (en) 2013-06-20 2015-12-03 Novo Nordisk A/S GLP-1 derivatives and uses thereof
US9498534B2 (en) * 2013-07-04 2016-11-22 Novo Nordisk A/S Derivatives of GLP-1 like peptides, and uses thereof
US11572398B2 (en) 2014-11-27 2023-02-07 Novo Nordisk A/S GLP-1 derivatives and uses thereof
CN107108714B (zh) 2014-12-17 2022-02-08 诺和诺德股份有限公司 Glp-1衍生物及其用途
US10118904B2 (en) 2015-06-05 2018-11-06 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of Demyelinating Diseases
WO2017112889A1 (en) 2015-12-23 2017-06-29 The Johns Hopkins University Long-acting glp-1r agonist as a therapy of neurological and neurodegenerative conditions
EP3423481B1 (en) 2016-03-03 2020-10-07 Novo Nordisk A/S Glp-1 derivatives and uses thereof
WO2018083335A1 (en) 2016-11-07 2018-05-11 Novo Nordisk A/S Dchbs-active esters of peg compounds and their use
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
CN108976147B (zh) * 2017-05-31 2021-02-12 首都医科大学 氨基正己酰氨基甲环酰氨基正己酰碱性氨基酸,其合成,活性和应用
CN109248323B (zh) * 2017-07-14 2023-09-08 杭州先为达生物科技有限公司 酰化的glp-1衍生物
BR112020001286A2 (pt) 2017-07-19 2020-07-28 Novo Nordisk A/S composto, e, método de tratamento da diabetes, sobrepeso e/ou doenças cardiovasculares
HRP20240485T1 (hr) 2017-08-24 2024-07-05 Novo Nordisk A/S Pripravci glp-1 i njihova upotreba
US11339111B2 (en) * 2017-11-30 2022-05-24 Societe Des Produits Nestle S.A. Polyketide compound and derivatives thereof for use in the prevention and treatment of a neurological disorder
LT3774862T (lt) 2018-04-05 2022-09-12 Sun Pharmaceutical Industries Limited Nauji glp-1 analogai
WO2019200594A1 (zh) 2018-04-19 2019-10-24 杭州先为达生物科技有限公司 酰化的glp-1衍生物
CN115814063A (zh) * 2018-04-19 2023-03-21 杭州先为达生物科技有限公司 Glp-1衍生物及其治疗用途
CN113024659B (zh) * 2018-04-19 2023-07-14 杭州先为达生物科技有限公司 酰化的glp-1衍生物
WO2020012604A1 (ja) * 2018-07-12 2020-01-16 三菱電機株式会社 半導体装置
CN115260313B (zh) 2019-12-31 2023-07-18 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
WO2021139744A1 (en) 2020-01-11 2021-07-15 Beijing Ql Biopharmaceutical Co., Ltd. Conjugates of fusion proteins of glp-1 and fgf21
US20230093542A1 (en) * 2020-02-18 2023-03-23 Novo Nordisk A/S Glp-1 compositions and uses thereof
CN114729060B (zh) 2020-09-30 2022-11-25 北京质肽生物医药科技有限公司 多肽缀合物和使用方法
CN114685644A (zh) * 2020-12-29 2022-07-01 苏州康宁杰瑞生物科技有限公司 一种人glp-1多肽变体及其应用
EP4288461A4 (en) 2021-07-14 2025-07-02 Beijing Ql Biopharmaceutical Co Ltd FUSION POLYPEPTIDES FOR METABOLIC DISORDERS
CN116848243B (zh) 2022-03-30 2024-03-19 北京质肽生物医药科技有限公司 多肽缀合物的液体药物组合物和其使用方法
CN121001710A (zh) 2022-12-30 2025-11-21 阿尔吉法玛公司 提高口服多肽治疗剂的全身生物利用度的组合物和方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458924B2 (en) * 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
WO1999043706A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S Derivatives of glp-1 analogs
BR0009040A (pt) 1999-03-17 2001-12-18 Novo Nordisk As Método para acilar um grupo amino de um peptìdeoou de uma proteìna, e, composto
EP1076066A1 (en) * 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
WO2001035988A1 (en) * 1999-11-12 2001-05-25 Novo Nordisk A/S Use of glp-1 agonists for the inhibition of beta cell degeneration
GB0020551D0 (en) 2000-08-22 2000-10-11 Birkett David Sprinkler system
AU2004231461B2 (en) 2003-03-19 2009-11-12 Eli Lilly And Company Polyethelene glycol linked GLP-1 compounds
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
BRPI0609676A2 (pt) 2005-05-13 2011-10-18 Lilly Co Eli composto de glp-1 peguilado,e, uso do mesmo
JP2011504871A (ja) 2007-06-01 2011-02-17 ノボ・ノルデイスク・エー/エス 固体又は半固体担体中にペプチド薬剤を含む自然に分散可能なプレコンセントレイト
ES2672770T3 (es) 2007-09-05 2018-06-18 Novo Nordisk A/S Derivados del péptido-1 similar al glucagón y su uso farmacéutico
JP5606314B2 (ja) 2007-09-05 2014-10-15 ノボ・ノルデイスク・エー/エス A−b−c−d−で誘導体化されたペプチドとその治療用途
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
CN102333788A (zh) 2009-02-19 2012-01-25 诺沃—诺迪斯克有限公司 因子viii的修饰
JP5411366B2 (ja) * 2009-12-16 2014-02-12 ノヴォ ノルディスク アー/エス 二重アシル化glp−1誘導体
EP2637698B1 (en) 2010-11-09 2022-04-20 Novo Nordisk A/S Double-acylated glp-1 derivatives
HUE031405T2 (en) * 2011-04-12 2017-07-28 Novo Nordisk As Double-acylated GLP-1 derivatives
US9498534B2 (en) * 2013-07-04 2016-11-22 Novo Nordisk A/S Derivatives of GLP-1 like peptides, and uses thereof

Similar Documents

Publication Publication Date Title
JP2017105819A5 (enExample)
JP2016523243A5 (enExample)
JP2016529253A5 (enExample)
JP2018505859A5 (enExample)
JP2019513126A5 (enExample)
JP2014529629A5 (enExample)
JP2014501712A5 (enExample)
JP2013543853A5 (enExample)
RU2013148921A (ru) Дважды ацилированные производные glp-1
US9546205B2 (en) Peptide analogues of glucagon and GLP1
JP4228398B2 (ja) 神経ペプチドy受容体拮抗剤
US20140221280A1 (en) Novel compounds and their effects on feeding behaviour
JP2008533105A5 (enExample)
JP2023071869A (ja) グルカゴンおよびglp-1受容体の長時間作用型コアゴニスト
JP2015517478A5 (enExample)
JP2015517477A5 (enExample)
RU2006144821A (ru) Пролонгирующие метки полипептидов, содержащие тетразольную группировку
RU2007134155A (ru) Glp-1 соединения с увеличенным временем полужизни
JP2010538049A5 (enExample)
JPWO2021160127A5 (enExample)
AU2014286234A1 (en) Derivatives of GLP-1 like peptides, and uses thereof
US20100305139A1 (en) Method of treating abnormal lipid metabolism
AU2012210308A1 (en) Novel compounds and their effects on feeding behaviour
JP2007519642A5 (enExample)
CN107205949A (zh) 包含片芯和立即释放包衣的用于口服glp‑1给药的药物组合物